Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · IEX Real-Time Price · USD
4.140
+0.310 (8.09%)
At close: Apr 18, 2024, 4:00 PM
4.150
+0.010 (0.24%)
After-hours: Apr 18, 2024, 5:43 PM EDT
Xenetic Biosciences Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Xenetic Biosciences.
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for XBIO is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '23 | Mar '23 | Apr '23 | May '23 |
|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 16, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +866.18% | Apr 11, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 → $40 | Strong Buy | Maintains | $50 → $40 | +866.18% | May 2, 2022 |
Financial Forecast
Revenue This Year
2.75M
from 2.54M
Increased by 8.43%
Revenue Next Year
1.84M
from 2.75M
Decreased by -33.33%
EPS This Year
-3.50
from -2.71
EPS Next Year
-0.84
from -3.50
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 2.8M | 1.9M | 2.4M |
| Avg | 2.8M | 1.8M | 2.3M |
| Low | 2.6M | 1.8M | 2.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 11.6% | -31.4% | 31.5% |
| Avg | 8.4% | -33.3% | 27.8% |
| Low | 4.2% | -35.9% | 22.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -3.60 | -0.86 | -0.81 |
| Avg | -3.50 | -0.84 | -0.79 |
| Low | -3.36 | -0.80 | -0.75 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.